Recent studies have shown that broad neutralizing antibody responses are found in about 20% of HIV-1 infected individuals and develop in most cases during the first two to three years following infecfion. In this program, we seek to study the dynamics and mechanism of development of broad neutralizing antibody responses through access to two large and well-characterized primary infection cohorts, Protocol C (donors from sub-Saharan Africa), and the First Choice Program (donors from Southern California). Our focus in this project will be to characterize the neutralizing specificifies as they emerge and evolve in individuals who develop broad and potent serum neutralizafion.
Our specific aims are:
Aim 1. To map the neutralizing specificities in the sera of individuals with broad and potent neutralizing Ab responses. This characterization will allow the selecfion of the most appropriate donors for isolafion of broadly neutralizing human monoclonal Abs (bNmAbs) in Aim 2 and the design of suitable baits for the isolafion of bNmAbs in collaboration with Project 2. A detailed analysis of the specificities responsible for broad serum neutralization will be carried out on the top 5% of neutralizers in the 2 cohorts.
Aim 2. To isolate and characterize bNmAbs from individuals selected in Aim 1. This informafion will be used to trace the evolutionary history of the broadly neutralizing responses in combination with Project 2. We will use the recently successful high-throughput direct functional screening strategy to isolate bNmAbs from four selected individuals from procedures in Aim 1. We will precisely map the epitopes recognized by the bNmABs. This informafion will be used to design
The field of AIDS vaccine is in great need of immunogens and immunizafion strategies able to efficiently induce broadly neutralizing antibodies. This project will use a novel approach to trace the path by which some individuals develop broadly neutralizing responses and thereby gain knowledge for the design of effective vaccines and vaccine strategies.
|Karris, Maile Y; Umlauf, Anya; Vaida, Florin et al. (2016) A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics. Medicine (Baltimore) 95:e5315|
|Krumm, Stefanie A; Mohammed, Hajer; Le, Khoa M et al. (2016) Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies. Retrovirology 13:8|
|MacLeod, Daniel T; Choi, Nancy M; Briney, Bryan et al. (2016) Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity 44:1215-26|
|Landais, Elise; Huang, Xiayu; Havenar-Daughton, Colin et al. (2016) Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. PLoS Pathog 12:e1005369|
|Var, Susanna R; Day, Tyler R C; Vitomirov, Andrej et al. (2016) Mitochondrial injury and cognitive function in HIV infection and methamphetamine use. AIDS 30:839-48|
|Doores, Katie J; Kong, Leopold; Krumm, Stefanie A et al. (2015) Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J Virol 89:1105-18|
|Shah, Kartik A; Clark, John J; Goods, Brittany A et al. (2015) Automated pipeline for rapid production and screening of HIV-specific monoclonal antibodies using pichia pastoris. Biotechnol Bioeng 112:2624-9|
|Frost, Simon D W; Murrell, Ben; Hossain, A S Md Mukarram et al. (2015) Assigning and visualizing germline genes in antibody repertoires. Philos Trans R Soc Lond B Biol Sci 370:|
|Murrell, Ben; Weaver, Steven; Smith, Martin D et al. (2015) Gene-wide identification of episodic selection. Mol Biol Evol 32:1365-71|
|Ozkumur, Ayca Yalcin; Goods, Brittany A; Love, J Christopher (2015) Development of a High-Throughput Functional Screen Using Nanowell-Assisted Cell Patterning. Small 11:4643-50|
Showing the most recent 10 out of 40 publications